Home Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple
 

Keywords :   


Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple

2016-03-15 21:31:47| Biotech - Topix.net

Investors on Tuesday are more interested in what may be the newest way in more than 40 years to better treat a type of deadly blood cancer than they are the next iteration of Apple Inc.'s iPhone. shot into the stratosphere late Monday after the company reported a late-stage, Phase 3 study showed its drug Vyxeos significantly improved the average survival of patients with acute myeloid leukemia , compared with the current standard-of-care chemotherapy.

Tags: of share market volume

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »